![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Medgenics | LSE:MEDU | London | Ordinary Share | COM SHS USD0.0001 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 392.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMMEDG TIDMMEDU
RNS Number : 7524D
Medgenics Inc
01 May 2013
Press Release 1 May 2013
Medgenics Announces Results of 2013 Annual Meeting of Stockholders
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announces that all resolutions proposed at the Company's Annual Meeting of Stockholders held yesterday were duly passed.
Each of the current directors of the Company, Dr. Sol J. Barer, Dr. Eugene A. Bauer, Mr. Isaac Blech, Dr. Alastair Clemow, Mr. Joseph J. Grano, Jr., Mr. Joel S. Kanter, Dr. Stephen D. McMurray and Dr. Andrew L. Pearlman, was reelected to the Board of Directors.
Stockholders also approved an amendment of the Company's Stock Incentive Plan, increasing the number of shares authorized to be issued under the plan by 1,700,000 shares.
Stockholders also approved, on an advisory basis, the compensation of the executive officers of the Company. Additionally, the option to request the stockholders to vote, on an advisory basis, on executive compensation every three years received the most votes cast.
Stockholders also ratified the appointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, to serve as the Company's independent registered public accounting firm for the year ended December 31, 2013.
Final voting tallies are subject to certification by the Company's inspector of elections and will be included in the Company's report, which is to be filed with the Securities and Exchange Commission within the next week.
About Medgenics
Medgenics is developing and commercializing Biopump(TM), a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia.
For further information, contact:
Medgenics, Inc. Phone: +972 4 902 8900 Dr. Andrew L. Pearlman andrew.pearlman@medgenics.com LHA Phone: 212-838-3777 Anne Marie Fields afields@lhai.com @LHA_IR_PR Abchurch Communications Phone: +44 207 398 7719 Adam Michael Joanne Shears Jamie Hooper jamie.hooper@abchurch-group.com Nomura Code Securities (NOMAD & Phone: +44 207 776 1200 Joint Broker) Jonathan Senior/Giles Balleny +44 207 776 1200 SVS Securities plc (Joint Broker) Phone: +44 207 638 5600 Alex Brearley
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMEAFSFEAPDEFF
1 Year Medgenics Chart |
1 Month Medgenics Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions